Image

Global Immune Thrombocytopenia Market – Industry Trends and Forecast to 2029

Pharmaceutical

Image

Global Immune Thrombocytopenia Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Oct 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Immune Thrombocytopenia Market – Industry Trends and Forecast to 2029

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period 2021–2029
Diagram Market Size (Base Year) USD 3.08 USD Billion
Diagram Market Size (Forecast Year) USD 3.35 USD Billion
Diagram CAGR %

Major Markets Players

  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

Global Immune Thrombocytopenia Market, By Type (Acute, Chronic), Treatment (Thrombopoietin Receptor Agonists, CorticosteroidsIntravenous Immunoglobulins and Others), Route of Administration (Oral, Injectable), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.

Immune Thrombocytopenia Market

Immune Thrombocytopenia Market Analysis and Size

The global immune thrombocytopenia market is expected to witness significant growth during the forecast period. Fast approvals from regulatory bodies such as the Food and Drug Administration (FDA) will impact the growth of the immune thrombocytopenia market. Major market players in the immune thrombocytopenia market also focus on expansion activities to promise seamless distribution. Autoimmune diseases, medications, pregnancy, chronic infections, and certain cancers are common secondary triggers of this disease. COVID-19 also had a major impact on the market growth.

Data Bridge Market Research analyses a growth rate in the global immune thrombocytopenia market in the forecast period 2022-2029. The expected CAGR of global immune thrombocytopenia market is tend to be around 1.04% in the mentioned forecast period. The market was valued at USD 3.08 billion in 2021, and it would grow upto USD 3.35 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Immune Thrombocytopenia Market Scope and Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Type (Acute, Chronic), Treatment (Thrombopoietin Receptor Agonists, Corticosteroids, Intravenous Immunoglobulins and Others), Route of Administration (Oral, Injectable), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Pfizer Inc (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Mylan N.V. (U.S.), Fresenius Kabi AG (Germany), Hikma Pharmaceuticals PLC (Japan), Hepalink Group. (China), Teva Pharmaceutical Industries Ltd. (Israel), Amarillo Biosciences, inc (U.S.), Bolder Bio Technology, Inc. (U.S.), GENOSCO Inc (U.S.), Hansa Biopharma (Sweden), Janssen Pharmaceuticals, Inc (Belgium), Eisai Co., Ltd (Japan)

Market Opportunities

  • Increasing Awareness About Blood Related Disorders
  • Rising Drug Approvals

Market Definition

Immune thrombocytopenia is a type of rare haematological bleeding disorders that is characterised by abnormally low level of blood platelet that results in the uncontrolled blood loss and wound. It is usually found in young women and in immunocompromised patients. A low platelet count causes extreme bleeding, which causes many symptoms of immune thrombocytopenia. In extreme cases, recurrent bleeding episodes can lead to anemia, which can induce fatigue and impede reaction to exertion. Severe bleeding into the brain can happen in rare situations. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period

Global Immune Thrombocytopenia Market Dynamics

Drivers

  • Increasing Mergers and Acqusitions

The growing number of merger and acquisitions have resulted in a significant market growth rate. For instance, in 2018, Dova Pharmaceuticals declared a collaboration with Shanghai Fosun Pharmaceuticals to develop and distribute Doptelet in China and Hong Kong. Likewise, Novartis declared the acquisition of oncology and pipeline department of Glaxo Smith Kline plc. The aim is to extend its business across the world and establish a wider customer reach. This boost the market growth.

  • Involvement of Multiple Strategies by Market Players

Different strategies adopted by major market players are expected to enhance the market in the region. For instance, Swedish Orphan Biovitrum AB (Sobi) acquired U.S.-based Dova Pharmaceuticals. This acquisition allowed Sobi to expand its product portfolio in hematology and support the commercial presence in the U.S.. This movements are helping in boosting the market growth.

Opportunities

  • Rising Drug Approvals

Pharmaceutical companies that are operating in the rare diseases arena have received approvals from the FDA in the last few years. For instance, in April 2018, Rigel Pharmaceuticals, Inc. got an approval for fostamatinib disodium hexahydrate tablets from the U.S. FDA for the treatment of thrombocytopenia in adult patients with immune thrombocytopenia. Furthermore, the European Medicines Agency (EMEA) recognized chronic immune thrombocytopenia as an orphan disease, with approximately 50,000 adult patients with chronic immune thrombocytopenia in the European Union.

  • Increasing Awareness About Blood Related Disorders

Rise in awareness about blood-related disorders and government initiatives for improving health care access in highly developing countries are projected to create significant opportunities in the global market.

Restraints/Challenges

  • Lack of knowledge in emerging markets

Lack of knowledge among the developing market players create a huge restraint in the market. Proper awareness and understanding is necessary for the flourishing business of the market. Several awareness programs should be conducted to increase the market growth and thus, in return will eliminate the hindrance.

  • High Cost of Treatment

The treatment involved in this disease such as Thrombopoietin Receptor Agonists, Corticosteroids, Intravenous Immunoglobulins, are a bit high-end. It requires huge expenditure. This factor hamper the growth of the market.

This global immune thrombocytopenia market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global immune thrombocytopenia market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Immune Thrombocytopenia Market

The COVID-19 pandemic has produced blockages in drug pipelines and supply chain activities in the health care sector. For market players, this has put unparalleled budget pressure on their expenditure. On the other hand, numerous medicinal regimens are being followed to cope with the rising pandemic. Multiple efforts have been made worldwide to provide a dependable and effective treatment for COVID-19. Manufacturing and the supply chains were stopped, resulting in losses to manufacturers, dealers, and consumers. Currently, the market is deteriorating; though, in the pre-pandemic era, as the condition improves, the demand is estimated to rise due to growing health concerns.

Recent Developments

  • In January 2021, Sobi (Swedish Orphan Biovitrum AB) declared the European Commission (EC) approval for Doptelet which is used for the treatment of primary chronic immune thrombocytopenia in adult patients.
  • Grifols SA decided to purchase GC Pharma Group's plasma fractionation and purification facilities in Montreal, along with 11 plasma collection centers in the U.S., in July 2020.

Global Immune Thrombocytopenia Market Scope

The global immune thrombocytopenia market is segmented on the basis of type, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

  • Acute
  • Chronic

Treatment

  • Thrombopoietin Receptor Agonists
  • Romiplostim
  • Eltrombopag
  • Avatrombopag
  • Lusutrombopag
  • Corticosteroids
  • Aristocort.
  • Bubbli-Pred
  • Celestone
  • Intravenous Immunoglobulins
  • Abaloparatide
  • Nintedanib
  • Risankizumab
  • Others

Route of Administration

End-Users

  • Hospitals
  • Homecare
  • Speciality Centres
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Immune Thrombocytopenia Market Regional Analysis/Insights

The global immune thrombocytopenia market is analysed and market size insights and trends are provided by type, treatment, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global immune thrombocytopenia market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to have the highest market growth due to the high demand for disease-specific treatment, the rise in adoption of newer technologies, the presence of refined healthcare expenditure, increased patient awareness, and the high prevalence of bleeding disorders.

Asia-Pacific dominates the market due to large number of generic manufacturer and rise in government initiatives and specialist communities.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Immune Thrombocytopenia Market Share Analysis

The global immune thrombocytopenia market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global immune thrombocytopenia market.

Key players operating in the g global immune thrombocytopenia market include:

  • Pfizer Inc (U.S.)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Mylan N.V. (U.S.)
  • Fresenius Kabi AG (Germany)
  • Hikma Pharmaceuticals PLC (Japan)
  • Hepalink Group. (China)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Amarillo Biosciences, inc (U.S.)
  • Bolder Bio Technology, Inc. (U.S.)
  • GENOSCO Inc (U.S.)
  • Hansa Biopharma (Sweden)
  • Janssen Pharmaceuticals, Inc (Belgium)
  • Eisai Co., Ltd (Japan)


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

FREQUENTLY ASK QUESTIONS

The immune thrombocytopenia market was USD 3.08 billion in 2021.
The immune thrombocytopenia market is projected to grow at a CAGR of 1.04% during the forecast period of 2022-2029.
Asia-Pacific dominates the market due to a large number of generic manufacturers and rises in government initiatives and specialist communities.
North America is expected to have the highest market growth due to the high demand for disease-specific treatment, the rise in adoption of newer technologies, the presence of refined healthcare expenditure, increased patient awareness, and the high prevalence of bleeding disorders.
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials